Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (275)	9/24/2002 1:47:14 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 7424

now 30%. sure would have been nice to see that news early. I was working on a reschedule for soccer. ugh.

To: tuck who wrote (275)	9/24/2002 2:02:37 PM
From: Jibacoa	Read Replies (1) \| Respond to of 7424

IDEV Is still up 40% for the day after the news that its Phase III trial of Trospium among patients suffering from overactive bladder (OAB) met both of its primary endpoints. biz.yahoo.com It had a good up-gap. siliconinvestor.com But it is still long way from closing its June 7 down-gap.<g> (That was the day when Pfizer informed IDEV that Pagoclone did not achieve the level of efficacy established in previous trials and Pfizer had elected not to pursue further development of the compound.) siliconinvestor.com Bernard